160 related articles for article (PubMed ID: 24560674)
21. Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine.
Qiu C; Huang Y; Wang Q; Tian D; Zhang W; Hu Y; Yuan Z; Zhang X; Xu J
Clin Infect Dis; 2012 Jan; 54(1):17-24. PubMed ID: 22052887
[TBL] [Abstract][Full Text] [Related]
22. [Local antibody immune responses in influenza patients and persons vaccinated with seasonal, pre-pandemic, and pandemic live attenuated influenza vaccines].
Donina SA; Petukhova GD; Koren'kov DA; Grigor'eva EP; Kuznetsova SA; Losev IV; Rudenko LG; Naĭkhin AN
Vopr Virusol; 2013; 58(3):37-42. PubMed ID: 24006632
[TBL] [Abstract][Full Text] [Related]
23. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
Petersson P; Hedenskog M; Alves D; Brytting M; Schröder U; Linde A; Lundkvist A
Vaccine; 2010 Sep; 28(39):6491-7. PubMed ID: 20637767
[TBL] [Abstract][Full Text] [Related]
24. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
[TBL] [Abstract][Full Text] [Related]
25. Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.
Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
Vaccine; 2018 Aug; 36(33):5097-5103. PubMed ID: 30007825
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1.
Nicolodi C; Groiss F; Kiselev O; Wolschek M; Seipelt J; Muster T
Vaccine; 2019 Jun; 37(28):3722-3729. PubMed ID: 31155415
[TBL] [Abstract][Full Text] [Related]
27. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
Treanor J; Nolan C; O'Brien D; Burt D; Lowell G; Linden J; Fries L
Vaccine; 2006 Jan; 24(3):254-62. PubMed ID: 16129526
[TBL] [Abstract][Full Text] [Related]
28. A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants.
Samdal HH; Bakke H; Oftung F; Holst J; Haugen IL; Korsvold GE; Kristoffersen AC; Krogh G; Nord K; Rappuoli R; Berstad AK; Haneberg B
Hum Vaccin; 2005; 1(2):85-90. PubMed ID: 17038826
[TBL] [Abstract][Full Text] [Related]
29. Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains.
Lee VJ; Tay JK; Chen MI; Phoon MC; Xie ML; Wu Y; Lee CX; Yap J; Sakharkar KR; Sakharkar MK; Lin RT; Cui L; Kelly PM; Leo YS; Tan YJ; Chow VT
Vaccine; 2010 Oct; 28(42):6852-7. PubMed ID: 20723626
[TBL] [Abstract][Full Text] [Related]
30. Mucosal immunization of CD4+ T cell-deficient mice with an inactivated virus induces IgG and IgA responses in serum and mucosal secretions.
Sha Z; Kang SM; Compans RW
Virology; 2005 Jan; 331(2):387-95. PubMed ID: 15629781
[TBL] [Abstract][Full Text] [Related]
31. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
[TBL] [Abstract][Full Text] [Related]
32. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.
Asahi-Ozaki Y; Yoshikawa T; Iwakura Y; Suzuki Y; Tamura S; Kurata T; Sata T
J Med Virol; 2004 Oct; 74(2):328-35. PubMed ID: 15332283
[TBL] [Abstract][Full Text] [Related]
33. Potential risk of repeated nasal vaccination that induces allergic reaction with mucosal IgE and airway eosinophilic infiltration in cynomolgus macaques infected with H5N1 highly pathogenic avian influenza virus.
Nakayama M; Itoh Y; Shichinohe S; Nakabayashi R; Ishigaki H; Sakoda Y; Le QM; Kawaoka Y; Kida H; Ogasawara K
Vaccine; 2017 Feb; 35(7):1008-1017. PubMed ID: 28109707
[TBL] [Abstract][Full Text] [Related]
34. Immunity to influenza in older adults with chronic obstructive pulmonary disease.
Gorse GJ; O'Connor TZ; Newman FK; Mandava MD; Mendelman PM; Wittes J; Peduzzi PN
J Infect Dis; 2004 Jul; 190(1):11-9. PubMed ID: 15195238
[TBL] [Abstract][Full Text] [Related]
35. Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate.
Ainai A; Suzuki T; Tamura SI; Hasegawa H
Viral Immunol; 2017; 30(6):451-462. PubMed ID: 28650274
[TBL] [Abstract][Full Text] [Related]
36. Sialivac: an intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry.
Worrall EE; Sudarisman ; Priadi A
Vaccine; 2009 Jun; 27(31):4161-8. PubMed ID: 19406183
[TBL] [Abstract][Full Text] [Related]
37. The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine.
Saito S; Ainai A; Suzuki T; Harada N; Ami Y; Yuki Y; Takeyama H; Kiyono H; Tsukada H; Hasegawa H
Vaccine; 2016 Feb; 34(9):1201-7. PubMed ID: 26802605
[TBL] [Abstract][Full Text] [Related]
38. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
[TBL] [Abstract][Full Text] [Related]
40. Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs.
Nishino M; Mizuno D; Kimoto T; Shinahara W; Fukuta A; Takei T; Sumida K; Kitamura S; Shiota H; Kido H
Vaccine; 2009 Sep; 27(41):5620-7. PubMed ID: 19647064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
